STOK
Stoke Therapeutics Inc

986
Mkt Cap
$1.7B
Volume
687,781.00
52W High
$38.69
52W Low
$5.35
PE Ratio
45.19
STOK Fundamentals
Price
$31.21
Prev Close
$29.82
Open
$29.95
50D MA
$27.80
Beta
1.26
Avg. Volume
1.35M
EPS (Annual)
-$1.65
P/B
5.33
Rev/Employee
$285,585.94
Loading...
Loading...
News
all
press releases
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Should You Buy?
Stoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Should You Buy...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
FY2025 Earnings Forecast for STOK Issued By Chardan Capital
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at Chardan Capital issued their FY2025 earnings estimates for Stoke Therapeutics in a research note issued on Wednesday, November...
MarketBeat·3d ago
News Placeholder
Stoke Therapeutics Target of Unusually High Options Trading (NASDAQ:STOK)
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) was the recipient of some unusual options trading on Friday. Stock traders bought 10,008 call options on the company. This is an increase of...
MarketBeat·4d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Director Adrian Krainer Sells 40,472 Shares
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Adrian Krainer sold 40,472 shares of the business's stock in a transaction dated Friday, November 14th. The shares were sold at an...
MarketBeat·7d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Trading Up 7.6% - Still a Buy?
Stoke Therapeutics (NASDAQ:STOK) Shares Up 7.6% - What's Next...
MarketBeat·7d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Director Sells $1,091,934.56 in Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Adrian Krainer sold 40,472 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, November 14th. The shares...
MarketBeat·7d ago
News Placeholder
19,300 Shares in Stoke Therapeutics, Inc. $STOK Purchased by Integrated Quantitative Investments LLC
Integrated Quantitative Investments LLC acquired a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the second quarter, according to its most recent Form 13F filing with...
MarketBeat·8d ago
News Placeholder
Los Angeles Capital Management LLC Makes New $224,000 Investment in Stoke Therapeutics, Inc. $STOK
Los Angeles Capital Management LLC acquired a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The...
MarketBeat·8d ago
News Placeholder
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·8d ago
News Placeholder
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today...
Business Wire·9d ago

Latest STOK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.